Enhancing Clinical Support for Breast Cancer with Deep Learning Models using Synthetic Correlated Diffusion Imaging

TL;DR

This study introduces a deep learning approach utilizing synthetic correlated diffusion imaging (CDI$^s$) MRI data to improve breast cancer clinical support, achieving better prediction of tumor grade and treatment response.

Contribution

First to develop a deep radiomic model based on CDI$^s$ MRI data for breast cancer, enhancing prediction accuracy over standard imaging modalities.

Findings

Improved prediction of tumor grade and treatment response.

Deep radiomic features outperform traditional methods.

Potential extension to other cancer applications.

Abstract

Breast cancer is the second most common type of cancer in women in Canada and the United States, representing over 25\% of all new female cancer cases. As such, there has been immense research and progress on improving screening and clinical support for breast cancer. In this paper, we investigate enhancing clinical support for breast cancer with deep learning models using a newly introduced magnetic resonance imaging (MRI) modality called synthetic correlated diffusion imaging (CDI$^s$). More specifically, we leverage a volumetric convolutional neural network to learn volumetric deep radiomic features from a pre-treatment cohort and construct a predictor based on the learnt features for grade and post-treatment response prediction. As the first study to learn CDI$^s$-centric radiomic sequences within a deep learning perspective for clinical decision support, we evaluated the proposed approach using the ACRIN-6698 study against those learnt using gold-standard imaging modalities. We find that the proposed approach can achieve better performance for both grade and post-treatment response prediction and thus may be a useful tool to aid oncologists in improving recommendation of treatment of patients. Subsequently, the approach to leverage volumetric deep radiomic features for breast cancer can be further extended to other applications of CDI$^s$ in the cancer domain to further improve clinical support.